BPS Bioscience Announces the Release of Over 65 Bromodomain Products

Nov. 9, 2012 - PRLog -- San Diego, CA – BPS Bioscience, Inc. (“BPS”) announced today the availability of more than 65 Bromodomain-related products including recombinant proteins, assay kits and the potent BET family bromodomain inhibitor – JQ1. Bromodomains (BRDs) are emerging as a new class of targets for cancer drug discovery and for the development of new inflammatory disease treatments. With over 50 proteins identified that contain one or more bromodomains, BPS’s offerings are the most extensive with 33 different bromodomains available and many more on the way.  In addition to these product offerings, BPS also provides BRD screening and profiling services for evaluation of potential new inhibitors.

Along with histone acetyltransferases and histone deacetylases, bromodomains have become a recent focus of pharmaceutical development. Bromodomains are proteins which bind to acetylated lysine residues, and are important for their epigenetic control via regulation of chromatin structure and gene expression. These protein domains are considered epigenetic “readers” since they provide the instructions for gene expression and can keep growth triggers permanently activated. Studies involving bromodomain inhibition suggest possible treatment of acute myeloid leukemia, BRD4-NUT midline carcinoma, multiple myeloma, and other fatal diseases, making the therapeutic potential expansive. In support of furthering this research, BPS Bioscience aims to make their portfolio of 30+ high quality bromodomain proteins, 11 assay kits and (+)-JQ1 bromodomain inhibitor easily accessible to all life scientists worldwide. BPS’s Director of Sales and Marketing, Dr. Suzan Oberle describes, “Bromodomains have been associated with numerous diseases processes, including cancer, viral replication, neurological disorders, and inflammation. We believe BRDs will be the next big class of protein targets for drug discovery.  Since BRDs bind to acetylated lysines, researchers working on HDACs and other proteins involved in gene regulation will find these products to be useful tools to identify inhibitors or activators of epigenetic pathways.” BPS Bioscience plans to release additional bromodomain proteins and assays in the coming months, and have a complete portfolio available by early 2013.

To learn more about these products, visit http://bpsbioscience.com/bromodomain or email info@bpsbioscience.com.

About BPS Bioscience
Headquartered in San Diego, California, the heart of one of the world's largest clusters of life science research institutes and companies, BPS Bioscience, Inc. is a leading producer for: Acetyltransferases, Bromodomains, Cytokines, HDACs, Histone Demethylases, Histone Methyltransferases, Kinases, Phosphatases, Phosphodiesterases, Poly ADP Ribose Polymerases, Proteases, and Ubiquitin Enzymes. BPS offers one of the largest selections of recombinant enzymes and assay kits for drug discovery and continues to expand its portfolio of innovative drug discovery products. BPS also provides custom protein expression, biochemical and cell-based assays, and compound screening and profiling services. BPS has provided products and services to pharmaceutical companies and academic institutes in over 45 countries worldwide. By being at the forefront of technology development, BPS focuses on providing quality life science products and services in a timely manner that will help our customers to accelerate drug discovery and development for treatment of human diseases. Visit BPS’s website for more information: http://www.bpsbioscience.com.